Phage Therapeutics International Inc – ‘10SB12G/A’ on 6/5/01 – EX-10.6

On:  Tuesday, 6/5/01, at 9:31pm ET   ·   As of:  6/6/01   ·   Accession #:  1096906-1-500109   ·   File #:  0-31961

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Amendment to Registration of Securities of a Small-Business Issuer   —   Form 10-SB
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10SB12G/A   Amendment to Registration of Securities of a          96    577K 
                          Small-Business Issuer                                  
 2: EX-3.(I)    Articles of Incorporation and Amendments               5     19K 
 3: EX-3.(II)   By-Laws                                               14     78K 
 4: EX-10.1     Advisory Agreements                                   11     68K 
 5: EX-10.2     Confidentiality Agreement                              2     11K 
 6: EX-10.3     Employee Agreements                                   47    237K 
 7: EX-10.4     Management Agreement                                   2     14K 
 8: EX-10.5     Property Lease Agreement                              26    138K 
 9: EX-10.6     Consulting Agreement                                   2±    11K 
10: EX-10.7     Stock Option Plan 2000                                17     85K 
11: EX-10.8     Securities Purchase Agreement                         28    139K 
12: EX-21       List of Subsidiaries                                   6     21K 
13: EX-27       Financial Data Schedule                                1     10K 

EX-10.6   —   Consulting Agreement
Exhibit Table of Contents

EXHIBIT 10.6
CONSULTING AGREEMENT

Consulting Agreement

THIS CONSULTING  AGREEMENT,  having an effective date of October 9, 2000 is made
between  Deirdre  (Dee)  E.  Sweeney,   doing  business  as  Sweeney  Regulatory
Consulting (herein referred to as "Consultant"),  18026 NE 133rd Street Redmond,
WA 98052  (SS####-##-####)  and Phage Therapeutics  International Inc., having a
mailing address as 19244-64th Place NE, Kenmore,  WA 98028-3380 (herein referred
to as "Client")                                                                 

The parties agree as follows:                                                   

(1)      Term. The Term of this Agreement shall be from October 16, 2000 through
         October  16,  2001.   Either  party  may   terminated   this  agreement
         immediately with cause, or upon 30 days prior to written notice without
cause.                                                        

(2)      Service to be Provided.  Consultant shall provide regulatory consulting
         services related to FDA requirements for submission of  Investigational
         New Drug  Applications  (INDs)  to  conduct  clinical  studies  used to
support the development and marketing of Client's products.   

(3)      Compensation.  During  the term of this  Agreement,  Client  shall  pay
         Consultant  a fee of $120 per  hour,  for  approximately  40 hours  per
         month,  the total amount payable monthly upon receipt of an invoice for
         services  to be sent to the  attention  of  Richard  Honour,  PhD.  The
         invoices  submitted by  Consultant  shall  provide the date and a brief
         description of services rendered,  and Client shall provide payment for
         approved  services within thirty (30 ) days of receipt of such invoice.
         Consultant  understands that she is an independent  contractor and will
         be  responsible  for her own  withholding  taxes  and  social  security
deductions.                                                   

         In addition, Client shall reimburse Consultant for actual and necessary
         out-of-pocket  expenses incurred (when  pre-approved by Client),  where
         such expenses are related to services  rendered  under this  Agreement,
such as overnight travel.                                     

(4)      Confidential Information and Property.  Consultant agrees that she will
         not disclose or use any Confidential  Information related to Client, or
         any  property of Client,  except as Client shall direct as described in
         the  "Confidential   Disclosure   Agreement"  signed  by  both  parties
(Attachment A).                                               

(5)      Entire  Agreement.  This agreement (and its attachment A) expresses the
         entire understanding  between the parties on the subject matter hereof.
         The provisions of this  agreement may not be waived or modified  except
         by a writing signed by the party against whom enforcement is sought. No
         waiver of breach shall constitute a subsequent waiver of any subsequent
         breach,  and if any provisions of this agreement are held to be invalid
         or  unenforeceable,  the  remaining  provisions  shall remain valid and
enforceable.                                                  

           Client:
           -------
  Sweeney Regulatory Consulting:          Phage Therapeutics International, Inc.

By   /s/ Deirdre E. Sweeney /s/         By     /s/ Richard C. Honour /s/    

Deirdre E. Sweeney                      Richard C. Honour                   

Its      Sole Proprietor                Its     Director                    

Date Signed       10-09-00              Date Signed       10-16-00          

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10SB12G/A’ Filing		Date		Other Filings
		10/16/01
Filed as of:		6/6/01
Filed on:		6/5/01		8-K
		10/16/00
		10/9/00
				List all Filings